10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2013 | |||
CONSOLIDATED STATEMENTS OF EARNINGS | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 14, 2014) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Net product sales | $ 12,304 | 13,654 | 17,622 |
| Alliance and other revenues | 4,081 | 3,967 | 3,622 |
| Total Revenues | 16,385 | 17,621 | 21,244 |
| Cost of products sold | 4,619 | 4,610 | 5,598 |
| Marketing, sellings and administrative | 4,084 | 4,220 | 4,203 |
| Advertising and product promotion | 855 | 797 | 957 |
| Research and development | 3,731 | 3,904 | 3,839 |
| Impairment charge for BMS-986094 intangible asset | 1,830 | ||
| Other (income)/expense | 205 | (80) | (334) |
| Total Expenses | 13,494 | 15,281 | 14,263 |
| Earnings Before Income Taxes | 2,891 | 2,340 | 6,981 |
| Provision for/(Benefit from) Income Taxes | 311 | (161) | 1,721 |
| Net Earnings | 2,580 | 2,501 | 5,260 |
| Net Earnings Attributable to Noncontrolling Interest | 17 | 541 | 1,551 |
| Net Earnings Attributable to BMS | 2,563 | 1,960 | 3,709 |
| Earnings per Common Share | |||
| Basic Earnings Per Common Share Attributable to BMS | 1.56 | 1.17 | 2.18 |
| Diluted Earnings per Common Share Attributable to BMS | 1.54 | 1.16 | 2.16 |
| Cash dividends declared per common share | 1.41 | 1.37 | 1.33 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2013 | |||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 14, 2014) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] | |||
| Net Earnings | $ 2,580 | 2,501 | 5,260 |
| Other Comprehensive Income (Loss), net of taxes and reclassifications to earnings [Abstract] | |||
| Derivatives qualifying as cash flow hedges | 7 | (27) | 56 |
| Pension and postretirement benefits | 1,166 | (118) | (742) |
| Available for sale securities | (37) | 3 | 28 |
| Foreign currency translation | (75) | (15) | (16) |
| Total Other Comprehensive Income/(Loss) | 1,061 | (157) | (674) |
| Comprehensive Income | 3,641 | 2,344 | 4,586 |
| Comprehensive Income Attributable to Noncontrolling Interest | 17 | 535 | 1,558 |
| Comprehensive Income Attributable to BMS | 3,624 | 1,809 | 3,028 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2013 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 14, 2014) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Cash Flows From Operating Activities: | |||
| Net Earnings | $ 2,580 | 2,501 | 5,260 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
| Net earnings attributable to noncontrolling interest | (17) | (541) | (1,551) |
| Depreciation and amortization | 763 | 681 | 628 |
| Deferred income taxes | (491) | (1,230) | 415 |
| Stock-based compensation | 191 | 154 | 161 |
| Impairment charges | 40 | 2,180 | 28 |
| Proceeds from Amylin diabetes alliance | 3,570 | ||
| Other adjustments | (9) | (35) | (147) |
| Changes in operating assets and liabilities: | |||
| Receivables | (504) | 648 | (220) |
| Inventories | (45) | (103) | (193) |
| Accounts payable | 412 | (232) | 593 |
| Other deferred income | 965 | 295 | 58 |
| Income taxes payable | 126 | (50) | (134) |
| Other | (466) | (897) | (58) |
| Net Cash Provided by Operating Activities | 3,545 | 6,941 | 4,840 |
| Cash Flows From Investing Activities: | |||
| Proceeds from sale and maturities of marketable securities | 1,815 | 4,890 | 5,960 |
| Purchases of marketable securities | (1,859) | (3,607) | (6,819) |
| Additions to property, plant and equipment and capitalized software | (537) | (548) | (367) |
| Proceeds from sale of businesses and other investing activities | 9 | 68 | 149 |
| Purchase of businesses, net of cash acquired | (7,530) | (360) | |
| Net Cash Used in Investing Activities | (572) | (6,727) | (1,437) |
| Cash Flows From Financing Activities: | |||
| Short-term debt borrowings/(repayments) | 198 | 49 | (1) |
| Proceeds from issuance of long-term debt | 1,489 | 1,950 | |
| Repayments of long-term debt | (597) | (2,108) | (78) |
| Interest rate swap terminations | 20 | 2 | 296 |
| Issuances of common stock | 564 | 463 | 601 |
| Repurchases of common stock | (433) | (2,403) | (1,221) |
| Dividends | (2,309) | (2,286) | (2,254) |
| Net Cash Used in Financing Activities | (1,068) | (4,333) | (2,657) |
| Effect of Exchange Rates on Cash and Cash Equivalents | 25 | (1) | (3) |
| Increase/(Decrease) in Cash and Cash Equivalents | 1,930 | (4,120) | 743 |
| Cash and Cash Equivalents at Beginning of Period | 1,656 | 5,776 | |
| Cash and Cash Equivalents at End of Period | 3,586 | 1,656 | 5,776 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2013 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2013 10-K (Filed: Feb 14, 2014) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2013 | Dec 31, 2012 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 3,586 | 1,656 |
| Marketable securities, current | 939 | 1,173 |
| Receivables | 3,360 | 3,083 |
| Inventories | 1,498 | 1,657 |
| Deferred income taxes, current | 1,701 | 1,597 |
| Prepaid expenses and other | 412 | 355 |
| Assets held-for-sale | 7,420 | |
| Total Current Assets | 18,916 | 9,521 |
| Property, plant and equipment | 4,579 | 5,333 |
| Goodwill | 7,096 | 7,635 |
| Other intangible assets | 2,318 | 8,778 |
| Deferred income taxes | 508 | 203 |
| Marketable securities, noncurrent | 3,747 | 3,523 |
| Other assets | 1,428 | 904 |
| Total Assets | 38,592 | 35,897 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term borrowings and current portion of long-term debt | 359 | 826 |
| Accounts payable | 2,559 | 2,202 |
| Accrued expenses | 2,152 | 2,573 |
| Deferred income, current | 756 | 825 |
| Accrued rebates and returns | 889 | 1,054 |
| Income taxes payable, current | 160 | 193 |
| Dividends payable | 634 | 606 |
| Liabilities related to assets held-for-sale | 4,931 | |
| Total Current Liabilities | 12,440 | 8,279 |
| Pension, postretirement, and postemployment liabilities | 718 | 1,882 |
| Deferred income, noncurrent | 769 | 4,024 |
| Income taxes payable, noncurrent | 750 | 648 |
| Deferred income taxes | 73 | 383 |
| Other liabilities | 625 | 475 |
| Long-term debt | 7,981 | 6,568 |
| Total Liabilities | 23,356 | 22,259 |
| Commitments and contingencies (Note 22) | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,369 in 2013 and 5,117 in 2012, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2013 and 2012 | 221 | 221 |
| Capital in excess of par value of stock | 1,922 | 2,694 |
| Accumulated other comprehensive loss | (2,141) | (3,202) |
| Retained earnings | 32,952 | 32,733 |
| Less cost of treasury stock - 559 million common shares in 2013 and 570 million in 2012 | (17,800) | (18,823) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 15,154 | 13,623 |
| Noncontrolling interest | 82 | 15 |
| Total Equity | 15,236 | 13,638 |
| Total Liabilities and Equity | 38,592 | 35,897 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |